PD-1 blockade alone or with platinum-based chemotherapy is indeed the first-line therapy (depending on the level of PDL1 expression) for non-targetable metastatic NSCLC, while never-smoking patients with NSCLC more often harbor a targetable molecular aberration. Here, CD274 is linked to non-small cell lung carcinoma.